TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Ticker SymbolTMDX
Company nameTransmedics Group Inc
IPO dateMay 02, 2019
CEODr. Waleed H. Hassanein, M.D.
Number of employees728
Security typeOrdinary Share
Fiscal year-endMay 02
Address200 Minuteman Road
CityANDOVER
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code01810
Phone19785520900
Websitehttps://www.transmedics.com/
Ticker SymbolTMDX
IPO dateMay 02, 2019
CEODr. Waleed H. Hassanein, M.D.
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data